The research team, led by Jocelyn Cruz-Perez and senior author Daniel San-Juan, identified patients through electronic medical records and applied the definition of status epilepticus established by the International League Against Epilepsy, the global body whose 2015 task force formalized both a time-based definition—roughly five minutes of continuous seizure activity for most seizure types—and a framework for classifying the condition by its cause and clinical features. Every patient included was at least eighteen years old and met criteria for refractory disease, meaning their seizures persisted despite appropriate first- and second-line antiseizure drug therapy. The investigators collected a wide sweep of clinical information for each patient: demographics, prior neurological history, imaging findings, laboratory values, electroencephalography recordings, medication exposures, duration of mechanical ventilation, length of hospital stay, and functional status at discharge from the neurological intensive care unit.

The demographic picture was striking for its youth. The median age of patients was just 34 years, with an interquartile range of 26 to 44, and 52.9 percent of the cohort were women. This is considerably younger than the typically elderly populations described in many high-income country series, where cerebrovascular disease and neurodegenerative conditions dominate the seizure landscape, and it reflects a different underlying epidemiology. In the Mexican cohort, 70.6 percent of patients had preexisting epilepsy before their refractory episode, while the remaining 29.4 percent experienced what clinicians call new-onset refractory status epilepticus, a seizure emergency erupting in a person with no prior diagnosis. When the researchers stratified their analysis by these two groups, as they had prespecified, important differences in both etiology and outcome emerged.

The leading causes of refractory episodes fell into three broad categories. Infections accounted for 23.5 percent of cases, structural and vascular causes—spanning strokes, tumors, and other focal brain lesions—accounted for 22.5 percent, and treatment-related factors, typically antiseizure medication withdrawal or inadequate drug levels in people with known epilepsy, accounted for 16.7 percent. The prominence of infectious etiologies, a pattern echoed in other series from low- and middle-income countries, underscores what the authors describe as preventable or modifiable contributors to catastrophic seizure emergencies. Central nervous system infections such as neurocysticercosis, a parasitic condition endemic to parts of Latin America, remain significant drivers of acute seizures in the region, and interrupted access to antiseizure medication is a well-documented trigger for breakthrough episodes in people with established epilepsy.

Electroencephalography, the cornerstone of diagnosis and monitoring in status epilepticus, most commonly revealed diffuse slowing of background rhythms in these patients, a finding associated with severe encephalopathic states. Interictal epileptiform discharges—the sharp, stereotyped waveform abnormalities that betray a brain prone to seizures—appeared in 27.7 percent of recordings. The reliance on EEG in this cohort highlights a persistent challenge in intensive care neurology: non-convulsive status epilepticus, in which the brain continues seizing electrically without visible convulsions, can only be detected by electroencephalography, and in resource-limited settings the availability of continuous EEG monitoring is often limited. The study’s institution, as Mexico’s national neurological referral center, represents one of the better-equipped environments in the country, yet the heterogeneity of monitoring documented in the series illustrates the practical constraints under which clinicians operate.

Treatment was markedly heterogeneous, mirroring the absence of a single universally validated protocol for refractory disease. An overwhelming 82.4 percent of patients required third-line therapy, typically continuous infusion of anesthetic agents such as midazolam, propofol, or ketamine, aimed at suppressing electrical seizure activity while systemic complications were managed in parallel. The median hospital stay stretched to 21.5 days, and patients spent an average of 8 days on mechanical ventilation—figures that convey the enormous intensity of care these episodes demand. Respiratory support, hemodynamic management, and prolonged sedation carry their own complications, and the burden of illness associated with super-refractory and prolonged disease is well recognized in the international literature as both clinically severe and economically significant. One patient in the cohort underwent surgery—resective neurosurgery directed at the epileptic focus—without complications, a reminder that in carefully selected cases, operative intervention can be part of the rescue arsenal when pharmacological strategies fail.

Perhaps the most encouraging finding was that despite the severity of the condition, resolution of status epilepticus was achieved in 87.3 percent of patients. That figure challenges a fatalistic view of refractory disease and aligns with emerging international evidence that aggressive, protocolized treatment can terminate even stubborn seizure emergencies, particularly in younger patients whose brains retain compensatory reserve. Functional outcomes at intensive care discharge, measured with the modified Rankin Scale—the ordinal scale from zero, indicating no symptoms, to six, indicating death—told a more nuanced story. While many patients left the unit with favorable functional status, unfavorable scores were significantly associated with preexisting epilepsy in the stratified analysis.

That association proved to be one of the study’s most clinically informative threads. Patients with preexisting epilepsy were significantly more likely to have experienced prior episodes of status epilepticus, more likely to achieve seizure resolution, paradoxically more likely to have an unfavorable modified Rankin Scale at discharge, and carried significantly higher scores on both the STESS and END-IT prognostic instruments. The Status Epilepticus Severity Score, developed by Rossetti and colleagues, incorporates age, seizure type, level of consciousness, and history of prior seizures to estimate outcome, while the END-IT score adds etiology, non-convulsive status, and mechanical ventilation to the prognostic equation. The finding that higher END-IT scores correlated with the need for third-line treatment suggests these prognostic tools may also help clinicians anticipate resource requirements—predicting which patients will need anesthetic infusions, prolonged ventilation, and extended intensive care bed occupancy.

The authors are careful to frame their findings within the limitations inherent to a retrospective single-center design, acknowledging that treatment decisions were made by individual treating teams over twelve years and were not standardized, and that follow-up extended only to intensive care discharge rather than long-term neurological outcome. Yet the value of the work lies precisely in its real-world texture. Systematic reviews of status epilepticus management in resource-limited settings have repeatedly identified a scarcity of local evidence as a barrier to guideline development, with most contemporary treatment algorithms derived from European and North American cohorts. Studies from India, Honduras, Morocco, and the Philippines have begun to fill that gap, and this Mexican series adds a substantial contribution from Latin America, a region where epilepsy care infrastructure varies widely and where antiseizure medication availability remains uneven, as documented by the International League Against Epilepsy’s own Task Force on Access to Treatment.

The broader message from the Mexican cohort is twofold. First, refractory status epilepticus in a tertiary Latin American setting is driven disproportionately by young patients, by preexisting epilepsy, and by infectious and treatment-related triggers—many of which are potentially preventable through better medication access, adherence support, and infection control. Second, even in a resource-constrained environment, the majority of these emergencies can be resolved, and favorable functional outcomes are often achievable. The study’s authors dedicate their findings, in part, to the multidisciplinary critical care teams whose work sustained patients through episodes lasting weeks. For a condition in which every minute of ongoing seizure activity compounds neuronal injury—the principle encapsulated in the aphorism that time is brain—the demonstration that 87.3 percent of refractory episodes ended in seizure cessation represents not merely a statistical result, but a proof of feasibility for intensive epilepsy care in settings long assumed to lack the capacity for it. Future work, the researchers suggest, should extend observation beyond discharge, standardize treatment protocols, and build multicenter networks across Latin America so that the next generation of evidence can guide policy as well as practice.